ホーム › 子宮内膜がん › ペンシルベニア › Philadelphia
Philadelphia、PAにおける子宮内膜がんの臨床試験
Philadelphiaとその周辺地域（約30マイル以内）の拠点で、子宮内膜がんに関する28件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
被験者募集中第3相
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 13マイル先
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Pennsylvania Hospital, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- 他4件
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
被験者募集中第1相
- NRG Oncology, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Philadelphia
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
被験者募集中第2相
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8マイル先
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Philadelphia
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
被験者募集中第2相
- Thomas Jefferson University, Philadelphia
- Lankenau Medical Center, Wynnewood · 7マイル先
- Asplundh Cancer Pavilion, Willow Grove · 13マイル先
- 他1件
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
被験者募集中第1/2相
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
被験者募集中第3相
- Hospital of the University of Pennsylvania ( Site 5007), Philadelphia
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
被験者募集中第2相
- University of Pennsylvania, Philadelphia
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- University of Pennsylvania, Philadelphia
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
被験者募集中第3相
- Research Site, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
被験者募集中第1相
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
被験者募集中第1相
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Philadelphia
- Research Site, Willow Grove · 13マイル先
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
被験者募集中第1相
- Sidney Kimmel Cancer Center, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
被験者募集中早期第1相
- Abramson Cancer Center at Penn Medicine, Philadelphia
- University of Pennsylvania Gynecologic Oncology Department, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Philadelphia
他の都市における子宮内膜がんの試験
- Houston, TX68件の研究
- New York City, NY52件の研究
- Boston, MA50件の研究
- Arlington, VA39件の研究
- Nashville, TN38件の研究
- Los Angeles, CA34件の研究
- St. Louis, MO29件の研究
- San Antonio, TX27件の研究
- Columbus, OH25件の研究
- Oklahoma City, OK25件の研究
- Chicago, IL25件の研究
- Queens, NY25件の研究
Philadelphiaにおける他の研究
- がん（全種類）59件の研究
- 乳がん56件の研究
- 非小細胞肺癌51件の研究
- 転移性癌46件の研究
- 前立腺がん44件の研究
- 大腸癌44件の研究
- 卵巣がん44件の研究
- 肺がん36件の研究
- 急性骨髄性白血病34件の研究
- 心不全31件の研究
- うつ病26件の研究
- 膵臓がん26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。